Prudential Financial Inc. grew its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL) by 262.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 627,530 shares of the biotechnology company’s stock after purchasing an additional 454,197 shares during the period. Prudential Financial Inc. owned approximately 0.21% of Exelixis worth $15,456,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the company. Vanguard Group Inc. lifted its holdings in shares of Exelixis by 12.8% during the 1st quarter. Vanguard Group Inc. now owns 23,735,071 shares of the biotechnology company’s stock valued at $514,339,000 after purchasing an additional 2,696,877 shares during the last quarter. Meditor Group Ltd lifted its holdings in shares of Exelixis by 5.5% during the 2nd quarter. Meditor Group Ltd now owns 20,229,713 shares of the biotechnology company’s stock valued at $498,258,000 after purchasing an additional 1,046,000 shares during the last quarter. BlackRock Inc. lifted its holdings in shares of Exelixis by 33,678.5% during the 1st quarter. BlackRock Inc. now owns 19,155,466 shares of the biotechnology company’s stock valued at $415,099,000 after purchasing an additional 19,098,757 shares during the last quarter. State Street Corp lifted its holdings in shares of Exelixis by 2.1% during the 1st quarter. State Street Corp now owns 7,710,338 shares of the biotechnology company’s stock valued at $167,087,000 after purchasing an additional 157,199 shares during the last quarter. Finally, Jennison Associates LLC lifted its holdings in shares of Exelixis by 10.1% during the 2nd quarter. Jennison Associates LLC now owns 2,873,349 shares of the biotechnology company’s stock valued at $70,771,000 after purchasing an additional 263,135 shares during the last quarter. Hedge funds and other institutional investors own 79.20% of the company’s stock.

Exelixis, Inc. (EXEL) opened at 25.97 on Friday. The company has a 50-day moving average price of $27.14 and a 200-day moving average price of $23.23. The stock has a market cap of $7.63 billion, a price-to-earnings ratio of 131.16 and a beta of 1.97. Exelixis, Inc. has a 52 week low of $10.04 and a 52 week high of $29.50.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported $0.06 earnings per share for the quarter, beating analysts’ consensus estimates of $0.04 by $0.02. Exelixis had a net margin of 18.20% and a return on equity of 80.43%. The firm had revenue of $99.01 million during the quarter, compared to analysts’ expectations of $85.27 million. During the same period in the previous year, the company earned ($0.15) earnings per share. Exelixis’s quarterly revenue was up 173.1% compared to the same quarter last year. Equities research analysts anticipate that Exelixis, Inc. will post $0.26 EPS for the current year.

Several brokerages have recently commented on EXEL. Piper Jaffray Companies reiterated a “buy” rating and set a $29.00 price objective on shares of Exelixis in a report on Thursday, August 3rd. Stifel Nicolaus reiterated a “hold” rating and set a $26.00 price objective on shares of Exelixis in a report on Thursday. Zacks Investment Research lowered Exelixis from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, June 28th. Deutsche Bank AG lowered Exelixis from a “buy” rating to a “hold” rating and raised their target price for the stock from $26.00 to $29.00 in a research note on Thursday, August 3rd. Finally, BidaskClub lowered Exelixis from a “strong-buy” rating to a “buy” rating in a research note on Monday, August 14th. Five investment analysts have rated the stock with a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $25.57.

TRADEMARK VIOLATION NOTICE: “Prudential Financial Inc. Has $15.46 Million Stake in Exelixis, Inc. (EXEL)” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another site, it was copied illegally and republished in violation of international trademark & copyright laws. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/09/09/prudential-financial-inc-has-15-46-million-stake-in-exelixis-inc-exel.html.

About Exelixis

Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.

Institutional Ownership by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Stock Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related stocks with our FREE daily email newsletter.